Can anyone with experience reading these reports summarize for us.
Are they selling any drug?
Yes, small but market penetration is better than expected by analyst. I would expect next quarter to be even better with Israel revenue and potentially Brazil giving approval.
EPS -6 cents with est at -9 to -12